Abstract
Virotherapy offers a new treatment strategy using oncolytic viruses as self-replicating, tumor-specific agents, which destroy tumors during their natural lytic replication process. To study potential oncolytic viruses, cell culture experiments give basic information about the lytic potential of a virus, measured as cell lysis or decreased viability. For further analysis, animal models are usually employed. As these in vivo experiments are often performed in immunocompromised animals, results have to be interpreted with caution. Therefore, to obtain deeper information of the oncolytic action of specific viruses in a patient’s individual context we established a test platform based on human primary tissue slices. In this three-dimensional model, we observed a preferential tumor infection and the penetration of oncolytic measles vaccine virus into deeper cell layers of tumor tissues, which is an essential feature of an effective oncolytic virus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Llovet, J. M., Burroughs, A., and Bruix, J. (2003) Hepatocellular carcinoma, Lancet 362, 1907–1917.
Bruix, J., and Llovet, J. M. (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology 35, 519–524.
Llovet, J. M., Fuster, J., and Bruix, J. (2002) Prognosis of hepatocellular carcinoma, Hepatogastroenterology 49, 7–11.
Burroughs, A., and Samonakis, D. (2004) Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?, Nat Clin Pract Gastroenterol Hepatol 1, 78–79.
Olinga, P., Merema, M., Hof, I. H., de Jong, K. P., Slooff, M. J., Meijer, D. K., and Groothuis, G. M. (1998) Effect of human liver source on the functionality of isolated hepatocytes and liver slices, Drug Metab Dispos 26, 5–11.
Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., and Knowles, B. B. (1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line, Nature 282, 615–616.
Knowles, B. B., Howe, C. C., and Aden, D. P. (1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen, Science 209, 497–499.
Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato, J. (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium, Cancer Res 42, 3858–3863.
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening, J Natl Cancer Inst 82, 1107–1112.
Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines, J Natl Cancer Inst 82, 1113–1118.
Shoemaker, R. H. (2006) The NCI60 human tumour cell line anticancer drug screen, Nat Rev Cancer 6, 813–823.
Wacker, W. E. C., Ulmer, D. D., and Vallee, B. L. (1956) Metalloenzymes and myocardial infarction, New England journal of medicine 225, 449.
Zimmermann, M., Armeanu, S., Smirnow, I., Kupka, S., Wagner, S., Wehrmann, M., Rots, M. G., Groothuis, G. M., Weiss, T. S., Konigsrainer, A., Gregor, M., Bitzer, M., and Lauer, U. M. (2009) Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses, Int J Oncol 34, 1247–1256.
Zimmermann, M., Lampe, J., Lange, S., Smirnow, I., Konigsrainer, A., Hann-von-Weyhern, C., Fend, F., Gregor, M., Bitzer, M., and Lauer, U. M. (2009) Improved reproducibility in preparing precision-cut liver tissue slices, Cytotechnology 61, 145–152.
Acknowledgments
We are grateful for grants from the Ministerium für Ernährung und Ländlichen Raum/Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (MLR/MWK Kap. 0802/98174), the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (BMBF 01GU503) and from the Deutsche Forschungsgemeinschaft SFB 773, project C3. We thank Prof. S. Russell (Mayo Clinic, Rochester, USA) for providing the MeV-GFP virus, furthermore Prof. Königsrainer (Department of General, Visceral and Transplant Surgery, Tuebingen, Germany), Prof. Falko Fend, and Prof. Bence Sipos (Department of Pathology, Medical University Hospital, Tuebingen, Germany) for providing primary tissue samples. We thank Johanna Lampe and Dr. Susanne Berchtold for proof reading.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Zimmermann, M., Weiland, T., Bitzer, M., Lauer, U.M. (2012). Preclinical Testing of Virotherapeutics for Primary and Secondary Tumors of the Liver. In: Mitry, R., Hughes, R. (eds) Human Cell Culture Protocols. Methods in Molecular Biology, vol 806. Humana Press. https://doi.org/10.1007/978-1-61779-367-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-61779-367-7_9
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-366-0
Online ISBN: 978-1-61779-367-7
eBook Packages: Springer Protocols